Clinical Update: TALEN-Edited CAR T-Cell Therapy...
Feb. 7, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Servier
Main focus: Gene editing for the development of CAR-T cells
Company stage: Clinical
Diseases: Haematological cancers and solid tumours
Genome editing tool: ARCUS genome-editing platform (licensed from Precision Biosciences), TALEN (Cellectis/Allogene Therapeutics)
Funding stage: Private
Location: Suresnes, France
Website: https://servier.com/en/
Pipeline: https://servier.com/en/areas-of-expertise/research-and-development/development-portfolio/
Partners: Allogene Therapeutics, Cellectis
Servier is a privately held, France-based, international big pharma company. The company has been in operation since 1954, and employs around 20,000 employees today. The company has established several contracts with high profile gene therapy companies, including a CAR-T development deal with Precision Biosciences and an allogeneic CAR-T deal with Allogene Therapeutics.
Tags
Related News and Updates
Clinical Trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT02746952)
Sponsors:
Institut de Recherches Internationales Servier
Sponsors:
Institut de Recherches Internationales Servier
IND Enabling
Phase I
Phase II
Phase III
Relapsed of Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT02808442)
Sponsors:
Institut de Recherches Internationales Servier
Sponsors:
Institut de Recherches Internationales Servier
IND Enabling
Phase I
Phase II
Phase III
